DNAH17 and hepatocellular carcinoma: For amplicon 1, the hypomethylation status of DNAH17 in HCC tissues was detected in patients with fibrous capsules (53.6% vs 70.7%, P = 0.0008, Figure 5A), tumor necrosis patients (56.1% vs 67.0%, P = 0.0370, Figure 5A), older patients (52.7% vs 62.4%, P = 0.0406, Figure 5A), AFP‐negative patients (49.9% vs 65.5%, P = 0.0010, Figure 5A), and male patients (56.1% vs 67.0%, P = 0.0076, Figure 5A).